Alpha Thalassemia: Genetic Deletions, Seven Subtypes and Clinical Consequences

Alpha thalassemia is the most common single-gene disorder in the world, yet most people who carry it never know. It starts with a simple imbalance: the body can’t make enough alpha-globin chains to pair with beta chains inside haemoglobin. Depending on how many of the four alpha-globin genes are switched off, and how, the result can be nothing at all, mild anaemia, a lifelong transfusion dependency, or a condition incompatible with life before birth. Understanding why one disorder produces such a wide range of outcomes means understanding exactly which genes are missing, and how.

What actually goes wrong in the genes 🔗

Every person carries four copies of the alpha-globin gene, two on each copy of chromosome 16 (called HBA1 and HBA2). Alpha thalassemia most often results from a deletion that removes one or more of these copies, though point mutations and insertions can also disrupt alpha chain production without deleting the gene itself. Since deletions are more common than point mutations, most people with reduced alpha output simply have fewer functioning copies of the gene rather than a broken copy. Whatever the mechanism, the outcome is the same: alpha chain production falls short, and the beta chains that would normally pair with them start to accumulate unpaired in red blood cells. That excess is what eventually causes the clinical damage, not the missing alpha chains themselves.

How common is it, and why does the rate swing so wildly 🔗

Carrier rates for alpha thalassemia vary more than almost any other inherited blood disorder, and India is a good example of why. The alpha thalassemia carrier rate across India has been reported to range from as low as 1% to as high as 80% depending on the community and region studied. The single-gene deletion known as -α3.7 is the most frequent mutation nationally, while a termination-codon variant called Hb Koya Dora reaches a notable 10% frequency in specific communities of Andhra Pradesh. Globally, the picture is just as uneven: carrier frequencies run around 5-10% in the Mediterranean basin, 20-30% in parts of West Africa, and as high as 60-80% in certain populations of Saudi Arabia, India, Thailand, Papua New Guinea, and Melanesia. In China, national averages are lower, but regional surveys in high-prevalence areas such as Hainan have found alpha thalassemia carrier rates climbing to around 40%, and as high as 55% in some ethnic minority populations.

What matters clinically is not just how many people carry a deletion, but which type they carry. India has comparatively fewer two-gene deletions on a single chromosome (called α0 genotypes) compared with Southeast Asia, which is part of why severe alpha thalassemia remains relatively rare here even though single-gene deletions are widespread.

The classic spectrum: severity tracks the number of genes lost 🔗

Four related conditions form a severity ladder, moving from completely silent to fatal as more of the four alpha-globin genes are knocked out.

Silent carrier: one gene missing 🔗

Also called α+-thalassemia, this is the mildest form. With three of four genes still working, red blood cell indices are usually normal or only borderline, and the person has no symptoms. It is picked up mostly during genetic counselling or family screening, not because of any complaint.

Alpha thalassemia trait or minor: two genes missing 🔗

This is where genotype starts to matter for family planning. If the two missing genes sit on the same chromosome (the cis arrangement, written –/αα), the person’s other chromosome is completely normal, but they carry a full α0 allele that can combine dangerously with a partner’s α0 allele in the next generation. If the two missing genes sit one on each chromosome (the trans arrangement, -α/-α), both chromosomes are affected but neither is a complete α0, which is a safer combination for offspring. Both genotypes usually cause mild microcytic anaemia that is often mistaken for iron deficiency.

Haemoglobin H disease: three genes missing 🔗

With only one functioning alpha gene left, alpha chain output falls sharply and the excess beta chains form unstable β4 tetramers, known as haemoglobin H (HbH). This produces moderate to sometimes severe haemolytic anaemia, jaundice, and an enlarged spleen, a picture often called thalassemia intermedia because it sits between the mild trait and the fatal form.

Hydrops fetalis or alpha thalassemia major: all four genes missing 🔗

When both parents carry the cis (α0) deletion, there is a one-in-four chance per pregnancy of a fetus inheriting all four missing genes. With no alpha chains at all, excess gamma chains form Hb Bart’s (γ4). This is generally fatal in utero or shortly after birth unless intrauterine transfusion is started early, and pregnancies are also at higher risk of pre-eclampsia and postpartum haemorrhage for the mother.

Hb Constant Spring: a mutation, not a deletion 🔗

Not every case of alpha thalassemia comes from a missing gene. Hb Constant Spring is caused by a point mutation at the stop codon of the alpha-2 gene, which tricks the ribosome into reading through and producing an abnormally long, unstable alpha chain. Hb Constant Spring is among the most common non-deletional alpha-globin variants in Southeast Asian populations, though comparable termination-codon variants such as Hb Koya Dora occur in specific Indian communities too. On its own, one copy of the Constant Spring gene behaves like a silent or mild carrier state. The real danger appears when it is co-inherited with an α0 cis deletion on the other chromosome: this combination produces a form of HbH disease that tends to be clinically more severe than deletional HbH disease, sometimes requiring regular transfusions, and in its most extreme homozygous form has been linked to fetal hydrops as well.

When alpha thalassemia comes with developmental effects: ATR-16 and ATR-X 🔗

Two rare, distinct syndromes pair alpha thalassemia with intellectual disability, and it is easy to confuse them because the phenotypes overlap.

ATR-16 syndrome results from a large deletion at the tip of chromosome 16p that removes not just the alpha-globin genes but a stretch of neighbouring genes as well. This contiguous gene deletion causes mild-to-moderate alpha thalassemia alongside intellectual disability, developmental delay, and variable dysmorphic features, with severity depending on exactly how much DNA is lost alongside the globin genes.

ATR-X syndrome, by contrast, is not a deletion at all. It is caused by mutations in the ATRX gene on the X chromosome, which encodes a chromatin-remodelling protein needed to keep the alpha-globin genes properly switched on. Because it is X-linked, ATR-X almost exclusively affects boys, who typically present with distinct facial features, more pronounced intellectual disability than ATR-16, and mild anaemia from reduced alpha chain output, even though their alpha-globin genes themselves are structurally intact.

ATMDS: alpha thalassemia that develops later in life 🔗

Every subtype discussed so far is inherited. Acquired alpha thalassemia with myelodysplastic syndrome (ATMDS) is different: it develops in adulthood, usually in older men who already have a bone marrow disorder called myelodysplastic syndrome. A somatic point mutation arises in the ATRX gene within the bone marrow’s blood-forming cells, silencing alpha-globin expression in those cells specifically. The alpha genes are structurally normal here; they are simply switched off in the affected cell population. The result is unexpectedly severe microcytic, hypochromic anaemia in someone who never carried an inherited thalassemia gene, alongside detectable HbH on blood testing. ATMDS is a useful reminder that alpha-globin regulation, not just the alpha-globin DNA sequence, can fail.

Why the biochemistry turns dangerous 🔗

Across almost every subtype, the underlying anaemia looks similar under the microscope: small, pale red blood cells, or a microcytic, hypochromic picture, caused by simply not having enough haemoglobin per cell. But the real damage comes from the leftover chains that pile up when alpha production fails. In HbH disease, the excess beta chains that form HbH tetramers are structurally unstable. They precipitate inside red blood cells as inclusion bodies, which damage the cell membrane and get filtered out by the spleen, shortening the red cell’s normal lifespan and driving chronic haemolysis.

In the fetal setting, the problem is different and more urgent. Hb Bart’s, made of four gamma chains, binds oxygen far more tightly than normal haemoglobin. This abnormally high oxygen affinity means Hb Bart’s holds onto oxygen instead of releasing it to tissues, leading to severe tissue hypoxia even when haemoglobin levels aren’t dramatically low. That hypoxia drives heart failure in the fetus, which shows up as generalised fluid accumulation, an enlarged liver and spleen, and a strikingly large placenta, the constellation known as hydrops fetalis. It’s a good illustration of a broader principle in these disorders: it’s rarely just the shortage of one chain that causes disease, it’s what the surplus of the other chain does once it’s left with no partner.

What do you think? If a single missing alpha gene can reach carrier rates of 60-80% in some populations without ever causing symptoms, does that change how seriously routine premarital or antenatal alpha thalassemia screening should be taken compared with beta thalassemia screening in India? And given how differently the cis and trans two-gene deletions behave for a couple planning a family, how much does knowing the exact genotype, not just the diagnosis, change the decisions a family should make?

References

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC3920506/
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3168153/
3. https://emedicine.medscape.com/article/955496-overview
4. https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2022.894444/full
5. https://www.orpha.net/en/disease/detail/163596
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC12750903/
7. https://www.sciencedirect.com/topics/medicine-and-dentistry/alpha-thalassemia-mental-retardation-syndrome
8. https://pubmed.ncbi.nlm.nih.gov/23092150/